- Bropirimine
-
- $0.00 / 1Kg
-
2020-05-03
- CAS:56741-95-8
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 800 ton
|
| 2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE Basic information |
| 2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE Chemical Properties |
Melting point | 285-287° (Stevens); mp 246-248° (Brown, Stevens) | Boiling point | 389.7±52.0 °C(Predicted) | density | 1.6292 (rough estimate) | refractive index | 1.6520 (estimate) | storage temp. | room temp | solubility | DMSO: ≥5mg/mL (warm DMSO) | form | powder | pka | 3.18; 8.53(at 25℃) | color | white to beige | Water Solubility | 7.8mg/L(37 ºC) |
Hazard Codes | Xn | Risk Statements | 63-62 | WGK Germany | 3 | RTECS | UW7351300 |
| 2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE Usage And Synthesis |
Description | Bropirimine is an immunomodulator with diverse biological activities. It is a toll-like receptor 7 (TLR7) agonist that inhibits RANKL-induced osteoclast differentiation of murine bone marrow-derived macrophages (BMDMs) in a concentration-dependent manner, an effect that is reversed by an anti-IFN-β antibody. Dietary administration of bropirimine (200 mg/kg twice per week) prevents development of transitional cell carcinomas (TCCs) in a mouse model of carcinogen-induced bladder carcinoma. Bropirimine (100 mg/kg) reduces pulmonary collagen accumulation and bronchoalveolar lavage fluid (BALF) monocyte and eosinophil infiltration in a hamster model of bleomycin-induced lung fibrosis. It also delays disease onset and progression and increases plasma IFN levels in a mouse model of experimental autoimmune encephalomyelitis (EAE). | Uses | Bropirimine, an immunostimulating agent and toll like receptor (TLR7) agonist, is used in comparison with other TLR7 agonists such as imiquimod, R-848, loxoribine in interferon cell signaling research. Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research. | Uses | Bropirimine is an orally active immunostimulant; anticancer agent. Bropirimine is an interferon inducer that is a potentially useful in the the treatment of superficial bladder cancer (transitional cell carcinoma). Studies suggest that Bropirimine has direct antitumor activity rather than a cytokine-mediated antitumor effect. | Definition | ChEBI: Bropirimine is a member of pyrimidines. | Biochem/physiol Actions | Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models. | storage | Desiccate at RT |
| 2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE Preparation Products And Raw materials |
|